Login
Login
Register
Complete Your Profile
Change Password
Request a Password Reset
Download Documents
Download Documents
Get Help to Participate in This Tender
Change Password
For better security, update the account password.
The DEPT OF DEFENSE | DEFENSE HEALTH AGENCY (DHA) has issued a Tender notice for the procurement of a Department of War Pharmacy Uniform Formulary Et Purchase Agreementuniform Formulary Additional Discount Program in the USA. This Tender notice was published on 07 Aug 2026 and is scheduled to close on 27 Aug 2026, with an estimated Tender value of Refer Document. Interested bidders can access detailed Tender information, eligibility criteria, and complete bidding documents by referencing TOT Ref No. 146745894, while the tender notice number is HT9402-26-Q-9402 and Registering on the platform.
Procurement Summary
Country: USA
Summary: Department of War Pharmacy Uniform Formulary Et Purchase Agreementuniform Formulary Additional Discount Program
Deadline: 27 Aug 2026
Posting Date: 07 Aug 2026
Other Information
Notice Type: Tender
TOT Ref.No.: 146745894
Document Ref. No.: HT9402-26-Q-9402
Competition: ICB
Financier: Self Financed
Purchaser Ownership: Public
Tender Value: Refer Document
Purchaser's Detail
Name: Login to see tender_details
Address: Login to see tender_details
Email: Login to see tender_detailsLogin to see details Tender Details The Department of War (DoW) is required by law (10 U.S.C. § 1074g) to establish an effective, efficient, integrated pharmacy benefits program for the Military Health System (MHS) which includes the purchase pharmaceutical agents. The law and implementing regulation (32 CFR Section 199.21) describe the process by which the DoW Pharmacy and Therapeutics (P&T) Committee will consider the relative clinical effectiveness and relative cost effectiveness of pharmaceutical agents in a therapeutic class in recommending the selection of agents for the DoW Uniform Formulary (UF) and, for cost sharing purposes, the classification of a pharmaceutical agent as generic, formulary, Basic Core Formulary (BCF), Extended Core Formulary (ECF), or non-formulary (NF). Prior to the scheduled P&T Committee meeting, a Request for Quotation (RFQ) for pharmaceutical agents within Drug Classes identified for placement on the UF has been issued to obtain quotes from industry. The Defense Health Agency may award Uniform Formulary Blanket Purchase Agreements (UF BPA) and the Uniform Formulary Additional Discount Program Agreements (UF ADP) based on the UF decision. This process is described in the attached RFQ. Documents
P&T COMMITTEE MEETING: The following November 2026 newly approved drugs will be reviewed:
a. Awiqli Flextouch - Insulin - Basal
b. Cavhanza - Leukemia and Lymphoma Agents - BCR-ABL Tyrosine Kinase Inhibitors
c. Lipfendra - Antilipidemics-1 - PCSK-9
d. Trutakna - Nephrology Agents Miscellaneous - NA
The RFQ, including UF BPA and UF ADP appendices, are attached herein. The instructions, important deadlines, and points of contact are in document, RFQ HT9402-26-Q-9402.
Pre-quotation teleconference is on August 12, 2026. Details are stated in Part 2.4. Pre-Quotation Teleconference. Responses to the clinical questions in Part 3.4 shall be submitted via e-mail to the RFQ POC in Part 2.3.1., no later than the date stated in Part 2.3.2.
Notice ID: ht9402-26-q-9402
Department/Ind. Agency: dept of defense
Sub-tier: defense health agency (dha)
Office: defense health agency
Product Service Code: 6505 - drugs and biologicals
NAICS Code: 325412 - Pharmaceutical Preparation Manufacturing
Inactive Dates: feb 02, 2027
Inactive Policy: manual
Procurement Documents for USA
Access a comprehensive library of standard procurement documents specific to USA. Here, you'll find all the essential forms, guidelines, and templates required for tender applications and submissions in USA
Want To Bid in This Tender?
Get Local Agent Support in USA and 60 More Countries.
View Tenders By
Sign in with Google